https://andersresearch.substack.com/archivedailyhttps://andersresearch.substack.com/aboutweeklyhttps://andersresearch.substack.com/p/alpha-tau-gaining-recognition-ahead2026-09-04monthlyhttps://andersresearch.substack.com/p/a-much-needed-paradigm-shift-in-ipf2026-05-04monthlyhttps://andersresearch.substack.com/p/gold-as-the-new-tina-during-the-ai2026-03-01monthlyhttps://andersresearch.substack.com/p/hinge-health-more-immune-to-ai-than2026-02-17monthlyhttps://andersresearch.substack.com/p/alpha-tau-drts-pancreatic-gbm-and2026-01-22monthlyhttps://andersresearch.substack.com/p/aktis-oncology-akts-largest-biotech2026-01-09monthlyhttps://andersresearch.substack.com/p/2025-wrap-up-portfolio-thoughts-and2025-12-23monthlyhttps://andersresearch.substack.com/p/a-high-risk-degenerate-gamble-before2025-12-15monthlyhttps://andersresearch.substack.com/p/immix-biopharma-thesis-playing-out2026-05-12monthlyhttps://andersresearch.substack.com/p/alpha-tau-medical-enabling-localized2025-10-15monthlyhttps://andersresearch.substack.com/p/fractyl-health-best-case-results2025-09-26monthlyhttps://andersresearch.substack.com/p/fractyl-health-one-time-procedure2025-09-05monthlyhttps://andersresearch.substack.com/p/invivyd-superior-covid-prophylaxis2025-09-12monthlyhttps://andersresearch.substack.com/p/alpha-cognition-2q25-earnings-recap2025-08-15monthlyhttps://andersresearch.substack.com/p/another-alzheimers-failure-recapping2025-07-01monthlyhttps://andersresearch.substack.com/p/inmune-bio-imminent-phase-2-alzheimers2025-06-16monthlyhttps://andersresearch.substack.com/p/alpha-cognition-launching-a-well2025-05-13monthlyhttps://andersresearch.substack.com/p/annovis-imminent-alzheimers-data2024-04-29monthlyhttps://andersresearch.substack.com/p/aquestive-therapeutics-aqst-underappreciated2024-03-20monthlyhttps://andersresearch.substack.com/p/annovis-potentially-encouraging-patient2024-03-30monthlyhttps://andersresearch.substack.com/p/maia-biotechnology-significantly2024-01-05monthlyhttps://andersresearch.substack.com/p/biovie-cautiously-optimistic-ahead2023-11-22monthlyhttps://andersresearch.substack.com/p/relmada-and-rel-1017-intriguing-underlying2023-10-17monthlyhttps://andersresearch.substack.com/p/immix-biopharma-a-mid-to-late-stage2025-12-11monthlyhttps://andersresearch.substack.com/p/annovis-making-sense-of-the-miscommunication2023-06-18monthlyhttps://andersresearch.substack.com/p/annovis-and-buntanetap-asymmetric2023-06-18monthlyhttps://andersresearch.substack.com/p/axsome-one-step-at-a-time2023-11-21monthlyhttps://andersresearch.substack.com/p/axsome-and-axs-05-a-special-situation2023-09-21monthly